ARS Pharmaceuticals, Inc. - Common Stock — Quarterly Cash Flow (NASDAQ:SPRY) | MetaTrader

Open full chart Full chart

Financials

Overview Statement Statistics

Quarterly Annual

Total assets 351.15 M327.32 M313.47 M372.8 M327.65 M287.57 M Total liabilities 94.36 M98.34 M121.15 M225.15 M213.39 M226.26 M Total equity 256.8 M228.97 M192.32 M147.66 M114.26 M61.31 M Total liabilities & shareholders' equities 351.15 M327.32 M313.47 M372.8 M327.65 M287.57 M Total debt —————— Net debt ——————

News

ARS Pharmaceuticals, Inc. (SPRY) Q1 2026 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Beats Revenue Estimates

ARS Pharmaceuticals Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most A

Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates

Merck KGaA (MKKGY) Surpasses Q1 Earnings and Revenue Estimates

Cronos Group (CRON) Q1 Earnings Meet Estimates

Collegium Pharmaceutical (COLL) Q1 Earnings and Revenues Beat Estimates

Earnings Preview: ARS Pharmaceuticals, Inc. (SPRY) Q1 Earnings Expected to Decline

ARS Pharmaceuticals, Inc. (SPRY) Soars 7.1%: Is Further Upside Left in the Stock?

ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines (SPRY)

Leerink raises ARS Pharmaceuticals stock price target on sales expansion

Earnings call transcript: ARS Pharmaceuticals beats Q4 2025 forecasts, stock rises